International Society for the Study of Women's Sexual Health

NEWS

Management of GSM in Women with a High Risk for Cancer: Consensus Recommendation

ISSWSH in collaboration with the North American Menopause Society (NAMS) is publishing consensus recommendations for the management of genitourinary syndrome of menopause in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies.

Read the Full Article


DYSPAREUNIA: CMS CLARIFICATION RESULTS IN EXPANDED TREATMENT AND COVERAGE UNDER MEDICARE PART D

ISSWSH is pleased to announce and recognize the Centers for Medicare and Medicaid Services (CMS) clarification of the statutory intent of “Prescription Drug Benefits” section 1860D-2(e)(2)(A) of the Social Security Act, stating that drugs for the treatment of moderate to severe dyspareunia (pain during sexual intercourse) due to menopause, are not excluded from Medicare Part D coverage when used consistent with this labeling.

ISSWSH, alongside the North American Menopause Society (NAMS), the American College of Obstetricians and Gynecologists (ACOG), and many other interested parties are committed to women’s health and particularly sexual health. James A. Simon, MD, President of ISSWSH, thanks these partners and commends CMS for this clarification that now allows women suffering from dyspareunia, to access expanded treatment options and get coverage under Medicare Part D.

View Press Release


ISSWSH PUBLICATION ON PROCESS OF CARE FOR HSDD NOW AVAILABLE IN MAYO CLINIC PROCEEDINGS

The International Society for the Study of Women’s Sexual Health (ISSWSH) is pleased to announce the publication of its Process of Care for Management of Hypoactive Sexual Desire Disorder (HSDD) in Women in Mayo Clinic Proceedings.  This milestone publication is the first to provide a consensus clinical management algorithm for the diagnosis and treatment of HSDD.

HSDD is a medical condition characterized by decreased or absent spontaneous or responsive sexual desire (i.e., sexual thoughts or fantasies) associated with negative emotional states and personal distress.  Women with HSDD experience increased healthcare costs, health burden, and decreased quality of life.  HSDD is the most common sexual dysfunction in women and studies in the US and Europe estimate its prevalence to be 6 – 19%.  Recent research and increasing public awareness of HSDD will increase the number of women seeking treatment from healthcare professionals.  The Process of Care for HSDD was developed to meet this unmet need.

Developed by 17 international expert panelists representing multiple healthcare disciplines and clinical specialties, the ISSWSH Process of Care for HSDD in Women provides evidence-based guidelines for the identification, diagnosis and treatment of this disorder in women that can be followed by non-expert primary care professionals and sexual medicine experts alike.  The Process of Care algorithm emphasizes biopsychosocial assessment and education, highlights opportunities to address modifiable factors, includes patient needs and preferences in the decision-making process, delineates evidence-based treatment options informed by reproductive status, and defines situations for specialized referral.  A separate ISSWSH panel of experts previously published a consensus white paper review on the epidemiology, nomenclature, pathophysiology and treatment strategies for HSDD for non-sexual medicine experts in Mayo Clinic Proceedings.

ISSWSH is a not-for-profit multidisciplinary, academic and scientific organization dedicated to supporting the highest standards of ethics and professionalism in research, education, and clinical practice of women's sexual health.  More information about the society and its activities can be obtained at:  http://www.isswsh.org.

Funding for the development of this Process of Care was provided by ISSWSH through unrestricted educational grants from Valeant Pharmaceuticals International, Inc, AMAG Pharmaceuticals, Emotional Brain BV, and Palatin Technologies, Inc.  The process of care algorithm was wholly developed under the auspices of ISSWSH with no participation or influence from industry.


Sunday, March 4th, Marks the 1st Annual International HPV Awareness Day – Spreading Knowledge and Prevention Around the Globe

This Sunday, March 4th the International Society for the Study of Women’s Sexual Health (ISSWSH) will be joining forces with around 80 organizations worldwide to commemorate the 1st annual International HPV Awareness Day. The goal of the day is to spark conversation and promote a worldwide exchange of ideas, knowledge, and research materials about human papillomaviruses (HPV) and their associated diseases.

Read more: Sunday, March 4th, Marks the 1st Annual International HPV Awareness Day – Spreading Knowledge and...


Expert Consensus Panel On Hsdd Article Recommended In F1000Prime

Hypoactive sexual desire disorder: international society for the study of women’s sexual health (ISSWSH) expert consensus panel review, authored by ISSWSH members Irwin Goldstein, Noel Kim, Anita Clayton, Leonard DeRogatis, Annamaria Giraldi, Sharon Parish, Jim Pfaus, and James Simon, has been recommended in F1000Prime as being of special significance in its field.

F1000 provides a rapidly updated consensus map of the important articles and trends across biology and medicine through the opinions and perspectives of over 10,000 peer-nominated international experts, the F1000 Faculty.


ISSM announces available Travel Stipends and Scholarships

ISSM is pleased to announce that 15 Travel Stipends will be provided to attendees of the 2016 World Meeting on Sexual Medicine being held in Beijing, China, September 2016.
Complete details on the stipends and an application can be found here: www.issm.info/grants1/travel-stipends-2016

Furthermore, ISSM will be providing 10 Scholarships to the ESSM School of Sexual Medicine taking place in Budapest, Hungary, October 2016.
Complete details on the Scholarships and an application can be found here: www.issm.info/grants1/issm-scholarships

Read more: ISSM announces available Travel Stipends and Scholarships


2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia.

In 2015, the International Society for the Study of Vulvovaginal Disease (ISSVD), International Society for the Study of Women's Sexual Health (ISSWSH) , and International Pelvic Pain Society (IPPS) adopted a new vulvar pain and vulvodynia terminology that acknowledges the complexity of the clinical presentation and pathophysiology involved in vulvar pain and vulvodynia, and incorporates new information derived from evidence-based studies conducted since the last terminology published in 2003. The article “2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia.” has been published simultaneously in the Journal of Lower Genital Tract Diseases and Obstetrics & Gynecology and will be published soon in the Journal of Sexual Medicine.

Please click here for link to article in Obstetrics & Gynecology.
Please click here for full text article in Journal of Lower Genital Tract Disease.


ISSWSH Press Release

PRESS RELEASE
 
Reference Articles:
Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women A Systematic Review and Meta-Analysis, Loes Jaspers; Frederik Feys; Wichor M. Bramer; Oscar H. Franco; Peter Leusink; Ellen T. M. Laan; JAMA Intern Med. doi:10.1001/jamainternmed.2015.8565, Published online February 29, 2016.
and the accompanying editorial
US Food and Drug Administration Approval of Flibanserin, Even the Score Does Not Add Up, Steven Woloshin; Lisa M. Schwartz; JAMA Internal Medicine Published online February 29, 2016.

Download PDF
- Press Release
- Bullet Points Reference Article
- Bullet Points Accompanying Editorial

February 29, 2016 -
Science has been corrupted by bias and personal agendas resulting in publication of a distorted analysis of outcomes of research trials. As authorities in the area of sexual function and dysfunction in women, in particular hypoactive sexual desire disorder (HSDD), the Board of Directors of the International Society for the Study of Women's Sexual Health (ISSWSH)1 is concerned that the aforementioned articles would be accepted by and published as quality science and factual commentary. According to Levine, the diverse controversies involving treatments for sexual difficulties have resulted in stakeholders interpreting science for us in ways that support their political ideological views, economic interests, or skill sets.2 This is clearly the case with regard to both the Jaspers et al. article and subsequent editorial response. We wish to set the record straight. When articles that reflect opinion rather than science are published in scientific journals, they harm those meant to be aided by science and medicine resulting, in this case, in a great disservice to the millions of pre-menopausal women suffering from HSDD.

Read more: ISSWSH Press Release


Scientific Program of the ISSWSH Annual Meeting 2016

We're excited to announce the availability of our full and detailed scientific program for the upcoming Annual Meeting to be held in Charleston, South Carolina, from February 25 to 28, 2016. For full details please visit http://www.isswshmeeting.org today. While you're there, please don't forget to register! See you in Charleston

2015 Consensus terminology and classification of persistent vulvar pain

Dear ISSWSH Members

Since the previous terminology of vulvodynia was accepted by the International Society for the Study of Vulvovaginal Disorders (ISSVD) in 2003, studies have explored possible causative factors and treatment options. The International Society for the Study of Women's Sexual Health (ISSWSH), The International Society for the Study of Vulvovaginal Disorders (ISSVD) and the International Pelvic Pain Society (IPPS) believed there was an unmet medical need for a comprehensive, evidence-based set of vulvovaginal pain diagnoses that can be easily utilized by both expert and non-expert healthcare providers to establish diagnoses in their patients and to guide treatment. Therefore we discussed the possibility of revision of 2003 terminology and organized an ISSWSH sponsored international meeting in order to reach a consensus on the terminology of vulvar pain, April 8 - 9, 2015 in Annapolis, Maryland. The American College of Obstetricians and Gynecologists (ACOG) and the National Vulvodynia Association (NVA) were also represented.

Read more: 2015 Consensus terminology and classification of persistent vulvar pain


Flibanserin approved as the FIRST pharmacologic treatment option for women suffering from hypoactive sexual desire disorder

Dear ISSWSH members,

It is with tremendous excitement that we share the announcement that flibanserin, a drug for acquired, generalized hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was approved by the FDA on August 18, 2015. This follows the June 4, 2015 meeting of their Advisory Committee whose members voted 18-6 for approval.

Read more: Flibanserin approved as the FIRST pharmacologic treatment option for women suffering from...


General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

Read more: General Statement of the International Society for the Study of Women's Sexual Health


FDA announced a Public Advisory Committee Meeting

FDA announced a Public Advisory Committee Meeting to review the approval of flibanserin for hypoactive sexual desire disorder (HSDD) in women on June 4, 2015. Should you wish to submit your written comments or request time at the public microphone, the deadline is a week away. Please find all details in the Federal Register Notice by clicking on this link. - -


Information about the ISSWSH Business Meeting

The ISSWSH Business Meeting will take place in the Capitol Ballroom A-D of the Sheraton Austin Hotel at the Capitol in Austin, TX on Friday February 20, 2015. The meeting is scheduled for 60 minutes from 5:00 - 6:00 pm.

Save the Date

ISSWSH Fall Course 2018
November 15-17, 2018   148 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH / ISSM Joint Meeting 2019
March 7-10, 2019   260 days left
Atlanta, GA, USA

Latest Tweets

Nationally representative sample of U.S. women finds that those who reported #genital dissatisfaction were less lik… https://t.co/kInm1DDTea ISSWSH
#Selfcompassion is important for all people and especially those recovering from #sexualpain disorders. Be nice to… https://t.co/uDQgmibCrf ISSWSH
Order the ISSWSH Textbook on Female Sexual Function and Dysfunction: Diagnosis and Treatment at… https://t.co/pqWyL763JM ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.